Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or North Carolina for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to North Carolina only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. North Carolina (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Eugene Wade (NPI 1548256266)

Field	Value
Entity Type	Individual
Organization	Eugene Wade
Address	1635 Nc Hwy 66 South
City	Kernersville
State	NC
ZIP	27284
Taxonomy	Family Medicine Physician
NPI Enumerated	September 27, 2005

Payer Source	Total Paid
Medicare	$7.2M
Medicaid	$0

Key Findings

This provider’s billed activity is effectively single‑payer: total Medicare revenue is $7.2M while Medicaid shows none on file, so Medicare dominates this provider’s reimbursement profile and any payer‑mix analysis should treat the practice as Medicare‑centric. The absence of Medicaid billing limits comparative in‑state Medicaid insights and suggests the provider does not participate materially in Medicaid‑funded infusion services.

Revenue is highly concentrated in a small set of biologic administration codes: the precomputed top 3 Medicare codes account for 54.0% of this provider’s total Medicare revenue, led by J3245 ($1.9M revenue, 27.1%), J9332 ($1.4M revenue, 20.3%), and J0517 ($474.8K revenue, 6.6%). This concentration indicates the business relies on a few high‑revenue injectable biologics for the bulk of Medicare receipts.

The code mix indicates an operational focus on on‑site drug administration and specialty biologic therapy rather than routine primary care visits: many top codes are J‑codes for monoclonal antibodies and other infused/ injected biologics (examples include J3245, J9332, J1459 and J0517), and multiple high‑volume infusion/administration CPTs are present (96365, 96366, 96372). Together these codes suggest the practice operates regular infusion and injection services—administering both chronic biologics and episodic IV therapies.

For several leading therapies this provider is a national outlier or near‑outlier: J3245 ranks #1 of 225 providers nationally (100th percentile; extreme outlier, far above typical national volume for this code), showing outsized market share in tildrakizumab administration; J9332 also ranks #1 of 5 providers nationally (100th percentile) though it is noted as a typical, unremarkable volume context for that code, indicating the national pool for J9332 is small. These rankings imply the provider is a dominant national supplier for certain specific drugs while the competitive interpretation can vary by drug due to niche market sizes.

Several infusion and administration CPTs and additional J‑codes show above‑typical volume, reinforcing the infusion‑centric service line: J3032 ranks #3 of 71 providers nationally (97th percentile; notably above typical national volume for this code), 96365 ranks #103 of 8873 providers nationally (99th percentile; notably above typical national volume for this code), 96366 ranks #87 of 2976 providers nationally (97th percentile; notably above typical national volume for this code), and 96372 ranks in the 99th percentile and is described as an extreme outlier. These patterns point to consistently higher use of infusion administration relative to most peers.

The provider plays a more modest role for some other high‑cost agents: J2350 contributes $290.4K (4.1%) but ranks #96 of 105 providers nationally (6th percentile; typical, unremarkable volume for this code), indicating limited participation for that specific drug despite nontrivial revenue. Analysts should therefore distinguish between dominant positions (e.g., J3245) and codes where the provider’s revenue is meaningful but the national rank indicates modest market share.

The practice also bills for a mix of supportive and specialty infusions beyond monoclonal antibodies—examples include J1459 (IVIG) at $398.1K (5.6%), J9312 (rituximab) at $217.4K (3.0%), and J1745 (infliximab) at $135.7K (1.9%). Presence of these products alongside chemotherapy administration codes such as 96413 ($32.9K) suggests the operation can handle a spectrum of infusion types from immune globulins to oncology‑related agents, which has implications for staffing, supply procurement, and payer contracting.

This profile is supported by long tenure: the NPI was enumerated on 2005-09-27 (~21 years ago), indicating an established operating history. For payers and competitors evaluating contracting or referral relationships, the combination of long tenure and a concentrated, infusion‑heavy revenue base signals a stable but specialized provider whose negotiating leverage and clinical niche will hinge on its dominance in a few high‑revenue biologics.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

29 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J3245	Injection, tildrakizumab, 1 mg	17,500	$110	$1.9M
J9332	Injection, efgartigimod alfa-fcab, 2mg	60,400	$20	$1.4M
J0517	Injection, benralizumab, 1 mg	3,570	$130	$474.8K
J1459	Injection, immune globulin (privigen), intravenous, non-lyophilized (e.g., liquid), 500 mg	10,760	$40	$398.1K
J2356	Injection, tezepelumab-ekko, 1 mg	24,780	$20	$371.7K
J2357	Injection, omalizumab, 5 mg	10,100	$30	$312.9K
J2350	Injection, ocrelizumab, 1 mg	6,600	$40	$290.4K
J2182	Injection, mepolizumab, 1 mg	11,800	$20	$271.4K
J3032	Injection, eptinezumab-jjmr, 1 mg	20,600	$10	$267.8K
J0129	Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered)	7,550	$30	$256.7K

Showing 1–10 of 29

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 29 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. North Carolina Distribution

Eugene Wade — 9 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — North Carolina

Full comparison — all codes billed, vs. state median

29 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9332	1	10	60,400	$20	$1.5M
J3245	1	10	3,400	$110	$640.2K
J2350	9	10	11,550	$40	$445.6K
J0129	43	70	9,530	$30	$393.2K
J1459	2	10	5,210	$40	$353.7K
J2356	1	10	19,950	$10	$276K
J2182	4	10	11,950	$20	$239.8K
J0517	2	10	840	$130	$222.3K
J9312	4	20	2,070	$60	$178.1K
J3032	1	10	6,300	$10	$137.6K

Showing 1–10 of 29

Related Providers

Other providers that share a Tax Identification Number (TIN) with Eugene Wade, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Jonathan Day	TX	Diagnostic Radiology Physician	$245.1K	$0
Jason Christie	IN	Vascular Surgery Physician	$92.3K	$0

Nearby Providers

Other providers in the same ZIP code as Eugene Wade, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Advantis Laboratories LLC	NC	Clinical Medical Laboratory	$322.9K	$448.1K
Adnan Javaid	NC	Pulmonary Disease Physician	$199.7K	$392.2K
Guardian Pharmacy Of Eastern Nc, LLC	NC	Long Term Care Pharmacy	$203.4K	$8.4K
Digestive Health Specialists, PA	NC	Ambulatory Surgical Clinic/Center	$124.3K	$13.5K
Andrew Chow	NC	Internal Medicine Physician	$85.8K	$0
Davonia Michael	NC	Anatomic Pathology & Clinical Pathology Physician	$82.2K	$0
Alexander Powers	NC	Neurological Surgery Physician	$55.6K	$0
Stephen Cockburn	NC	Neurology Physician	$53K	$0
Kernersville Pharmacy LLC	NC	Community/Retail Pharmacy	$52.7K	$0
Jennifer Harvey	NC	Family Medicine Physician	$28.5K	$0

Eugene Wade — Billing Profile & Reimbursement Data

Sign up for Eugene Wade — Billing Profile & Reimbursement Data policy alerts

Eugene Wade — Billing Profile & Reimbursement Data

Sign up for Eugene Wade — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References